ArticlePloS one2025
Lycopene inhibits ER stress and apoptosis while modulating PI3K/AKT and enhancing antioxidant and anti-apoptotic proteins.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a critical clinical syndrome with limited therapeutic options. This study investigated the renoprotective effects of lycopene, a potent antioxidant, in both in vivo and in vitro AKI models. In a murine cecal ligation and puncture (CLP)-induced sepsis-AKI model, pretreatment with lycopene (10, 20, 40 mg/kg) dose-dependently ameliorated renal histopathological damage (HE staining) and restored serum biomarkers (AST, ALT, BUN, CREA). Mechanistically, lycopene suppressed oxidative stress and apoptosis by downregulating the PI3K/Akt axis: it significantly reversed the CLP-induced upregulating of p-PI3K and p-Akt, and the pro-apoptotic proteins (Bax, Cleaved Caspase-3), while increasing Nrf 2 and SOD1. Consistent results were observed in LPS- and H₂O₂-induced cellular AKI models, where lycopene attenuated cell death and restored redox homeostasis in a dose-dependent manner. Immunofluorescence assays further validated these trends. Crucially, PI3K siRNA or cDNA transfection experiments confirmed that lycopene's antioxidant and anti-apoptotic effects were PI3K-dependent. Our findings highlight lycopene as a promising therapeutic agent for AKI, acting via PI3K/Akt-mediated activation of Nrf 2 to counteract oxidative damage and apoptosis. This study provides novel insights into the molecular mechanisms underlying lycopene's renoprotection and supports its potential clinical translation for sepsis or oxidative stress-associated AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.